×
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$44.82
+0.49 (+1.11%)
(As of 05/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$43.75
$45.16
50-Day Range
$36.78
$44.82
52-Week Range
$31.36
$46.62
Volume
826,647 shs
Average Volume
946,941 shs
Market Capitalization
$6.18 billion
P/E Ratio
14.99
Dividend Yield
N/A
Beta
1.24
30 days | 90 days | 365 days | Advanced Chart
Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Halozyme Therapeutics logo

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
145
Year Founded
1998

Sales & Book Value

Annual Sales
$443.31 million
Cash Flow
$2.05 per share
Book Value
$1.89 per share

Profitability

Net Income
$402.71 million
Pretax Margin
62.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
134,777,000
Market Cap
$6.18 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/25/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

444th out of 1,420 stocks

Biological Products, Except Diagnostic Industry

72nd out of 209 stocks

Analyst Opinion: 2.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -













Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

Is Halozyme Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Halozyme Therapeutics stock.
View analyst ratings for Halozyme Therapeutics
or view top-rated stocks.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Halozyme Therapeutics
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by $0.02. The biopharmaceutical company earned $117.30 million during the quarter, compared to analyst estimates of $128.25 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 132.71% and a net margin of 92.23%. The business's revenue was up 31.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 EPS.
View Halozyme Therapeutics' earnings history
.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided EPS guidance of $2.05-$2.20 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of $530.00 million-$560.00 million, compared to the consensus revenue estimate of $566.18 million.

What price target have analysts set for HALO?

4 Wall Street analysts have issued 1-year target prices for Halozyme Therapeutics' shares. Their forecasts range from $42.00 to $58.00. On average, they anticipate Halozyme Therapeutics' share price to reach $51.50 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts' price targets for Halozyme Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the following people:
  • Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., Pres, CEO & Director (Age 59, Pay $1.65M)
  • Dr. Michael J. LaBarre, Sr. VP & Chief Technical Officer (Age 58, Pay $779.55k) (LinkedIn Profile)
  • Ms. Nicole LaBrosse, Sr. VP & CFO (Age 39)
  • Ms. Melinda Hutcheon, Director of Investor Relations & Corp. Communications
  • Mr. Mark Snyder Esq., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Amy Marinne Fox, VP of HR
  • Dr. Steve Knowles MBBS, Chief Medical Officer
  • Mr. Todd Butler, Chief of Staff to the CEO, VP & Head of Project Management
  • Dr. Christopher Bryant Ph.D., Sr. VP of Technical Operations & Chief Manufacturing Officer (Age 61)
  • Ms. Fionnuala Doyle, Sr. VP & GM of ENHANZE
What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics CEO Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among Halozyme Therapeutics' employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.62%), William Blair Investment Management LLC (3.88%), Invesco Ltd. (3.86%), Snyder Capital Management L P (2.93%), Northern Trust Corp (1.63%) and Loomis Sayles & Co. L P (1.59%). Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre.
View institutional ownership trends for Halozyme Therapeutics
.

Which institutional investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Skandinaviska Enskilda Banken AB publ , Vanguard Group Inc., Invesco Ltd., Federated Hermes Inc., UBS Group AG, WINTON GROUP Ltd, and Eagle Asset Management Inc.. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, Jean-Pierre Bizzari, and Michael J Labarre.
View insider buying and selling activity for Halozyme Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Loomis Sayles & Co. L P, Bernzott Capital Advisors, Sectoral Asset Management Inc., GW&K Investment Management LLC, Russell Investments Group Ltd., First Light Asset Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Halozyme Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $44.82.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics has a market capitalization of $6.18 billion and generates $443.31 million in revenue each year. The biopharmaceutical company earns $402.71 million in net income (profit) each year or $2.989990 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

Halozyme Therapeutics employs 145 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

When was Halozyme Therapeutics founded?

Halozyme Therapeutics was founded in 1998.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is www.halozyme.com.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at [email protected], or via fax at 858-704-8311.

This page was last updated on 5/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.